Miromatrix to Report Third Quarter 2022 Financial Results
Miromatrix Medical Inc. (NASDAQ: MIRO) will announce its third quarter 2022 financial results after the market close on November 14, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO) will announce its third quarter 2022 financial results after the market close on November 14, 2022. The company is dedicated to bioengineering transplantable organs to address organ shortages. A conference call will follow at 3:30 PM Central Time, where management will discuss the results. Interested parties can join by phone or via a live webcast on the Miromatrix investor relations website. The firm focuses on developing organs, primarily human livers and kidneys, using its proprietary perfusion technology.
Positive
- Company's focus on bioengineering transplantable organs addresses a critical shortage.
- Development of proprietary perfusion technology could lead to scalable solutions for organ shortages.
Negative
- None.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was +11.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the third quarter 2022 after market close on Monday, November 14, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13732863. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.